Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  ruxolitinib phosphate
Find trials that include:  Any drugs shown
Results 1-25 of 31 for your search:
Start Over
Study of Ruxolitinib in Pancreatic Cancer Patients (Janus 1)
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: INCB 18424-362, NCI-2014-01324, NCT02117479
A Study of Ruxolitinib in Pancreatic Cancer Patients
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: INCB 18424-363, NCI-2014-01487, NCT02119663
Momelotinib Versus Ruxolitinib in Subjects With Myelofibrosis
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: GS-US-352-0101, NCI-2013-02398, 2013-002707-33, NCT01969838
Ruxolitinib for Chronic Myeloid Leukemia (CML) With Minimal Residual Disease (MRD)
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 2012-0697, NCI-2013-00551, NCT01751425
A Sequential Two-Stage Dose Escalation Study to Evaluate the Safety and Efficacy of Ruxolitinib
Phase: Phase II, Phase I
Type: Treatment
Age: Over 18
Trial IDs: MCC 17259, NCI-2013-00540, 12.12.0017, NCT01776723
Ruxolitinib Phosphate and Chemotherapy before Surgery in Treating Patients with Recurrent, Metastatic, or Triple-Negative Inflammatory Breast Cancer
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 13-494, NCI-2015-00620, I-Rux-12-06, NCT02041429
Ruxolitinib Phosphate and Trastuzumab in Treating Patients with Metastatic HER2-Positive Breast Cancer
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: AAAM1906, NCI-2014-02015, NCT02066532
Ruxolitinib Phosphate and Decitabine in Treating Patients with Myeloproliferative Neoplasms
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: MPD-RC 109, NCI-2014-01264, GCO 13-1816, MPD-RC 107, NCT02076191
Ruxolitinib Phosphate and Decitabine in Treating Patients with Relapsed or Refractory or Post Myeloproliferative Acute Myeloid Leukemia
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 2014-0344, NCI-2014-02299, NCT02257138
Ruxolitinib Phosphate or Dasatinib with Chemotherapy in Treating Patients with Relapsed or Refractory Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia
Phase: Phase II, Phase I
Type: Treatment
Age: 10 and over
Trial IDs: 2014-0521, NCI-2015-00779, NCT02420717
Ruxolitinib Phosphate (Oral JAK Inhibitor INCB18424) in Treating Patients with Relapsed or Refractory Diffuse Large B-Cell or Peripheral T-Cell Non-Hodgkin Lymphoma following Donor Stem Cell Transplant
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 19 and over
Trial IDs: 283-11, NCI-2011-02733, 12C0196, NCT01431209
Ruxolitinib Phosphate in Treating Patients With Metastatic or Locally Advanced Breast Cancer That Cannot Be Removed By Surgery
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 12-024, NCI-2012-00992, NCT01562873
Ruxolitinib (INCB018424) in Subjects With Primary Myelofibrosis, Post Essential Thrombocythemia-myelofibrosis and Post Polycythemia Vera-myelofibrosis
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: INCB18424-258, NCI-2011-03132, NCT01348490
Ruxolitinib Phosphate in Treating Patients With Adult T-Cell Leukemia
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 13-C-0006, NCI-2013-01560, 130006, 335354, P12996, NCT01712659
Ruxolitinib Phosphate and Exemestane in Treating Patients With Estrogen Receptor-Positive Metastatic Breast Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: UPCC 02112, NCI-2012-00745, NCT01594216
Ruxolitinib Phosphate and Azacytidine in Treating Patients with Myelofibrosis or Myelodysplastic Syndrome/Myeloproliferative Neoplasm
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 2012-0737, NCI-2013-00704, NCT01787487
Ruxolitinib Phosphate Before Reduced Intensity Donor Stem Cell Transplant in Treating Patients with Myelofibrosis
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 70
Trial IDs: MPD-RC 114, NCI-2014-01258, 12-00826, 12-1809, GCO 12-1809, NCT01790295
Ruxolitinib Phosphate in Treating Patients with Chronic Neutrophilic Leukemia or Atypical Chronic Myeloid Leukemia
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 10262, NCI-2014-00633, NCT02092324
Ruxolitinib in Combination With Pemetrexed/Cisplatin in Non Small Cell Lung Cancer
Phase: Phase II
Type: Treatment
Age: 18 to 75
Trial IDs: INCB 18424-266, NCI-2014-01067, NCT02119650
Study of Ruxolitinib in Colorectal Cancer Patients
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: INCB18424-267, NCI-2014-01443, NCT02119676
A Study of Ruxolitinib in Combination With Capecitabine in Subjects With Advanced or Metastatic HER2-negative Breast Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: INCB 18424-268, NCI-2014-01409, NCT02120417
Ruxolitinib Phosphate in Reducing Fatigue in Patients with Chronic Lymphocytic Leukemia
Phase: Phase II
Type: Supportive care
Age: 18 and over
Trial IDs: 2013-0044, NCI-2014-01465, NCT02131584
JAK-2 Inhibitor before Donor Stem Cell Transplant in Treating Patients with Primary or Secondary Myelofibrosis
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 7 months and over
Trial IDs: 9033, NCI-2014-01882, FH9033, NCT02251821
A Phase 2 Study Of PRM-151 In Subjects With Myelofibrosis
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: PRM-151G-101, NCI-2013-02329, NCT01981850
Start Over